FDA Approves Ketamine-Derived Nasal Spray to Treat Severe Depression

Ketamine for induction and maintenance of anesthesia and acute pain treatment. Shutterstock

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s ketamine-derived nasal spray Spravato to treat those with severe depression, the company said on Tuesday. 

The drug was first approved in 2019 in combination with antidepressants to treat major depressive disorder.